Abstract:4003 1 alpha, 25-dihydroxy vitamin D 3 (1,25(OH) 2 D 3 ) demonstrates strong antiproliferative effects in a variety of cancer cell types including prostate cells while the PI3K/AKT pathway presents a pro-survival pathway implicated in prostate cancer. The antiproliferative effect of 1,25(OH) 2 D 3 almost universally involves upregulation of p21 and/or p27, while loss of PTEN and activation of PI3K/AKT can downregulate p21 and p27 levels by a number of mechanisms. We hypothesized that 1,25(OH) 2 D 3 signaling is antagonized by PI3K/AKT signaling. To test this we isolated Pten WT mouse prostatic epithelial cells (MPECs) from Pten floxed, Cre-negative mouse prostates and Pten null MPECs from the Pten lox/lox prostates where Pten was deleted by probasin-driven Cre-recombinase. We found that while Pten WT MPECs were significantly growth-inhibited by 1,25(OH) 2 D 3 , Pten null MPECs were completely unresponsive to 1,25(OH) 2 D 3 . By shRNA knockdown and by in vitro knockout of Pten in WT MPECs we then showed that Pten loss itself is insufficient to antagonize 1,25(OH) 2 D 3 -mediated growth suppression. To evaluate the ability of PI3K/AKT to antagonize 1,25(OH) 2 D 3 -mediated growth inhibition we used an inhibitor of PI3K/AKT - LY294002 and an inhibitor of AKT - SH-5. Pre-treatment of insensitive Pten-/- MPECs with LY294002 or SH-5 partially restored the sensitivity to and synergized with the antiproliferative actions of 1,25(OH) 2 D 3 . We extended the study to the human prostate cancer cell line LNCaP which is only moderately responsive to 1,25(OH) 2 D 3 . LY294002 and 1,25(OH) 2 D 3 treatment demonstrated statistically significant synergistic inhibition of LNCaP cell growth (CI=0.171 at 0.2μM LY294002 and 1nM 1,25(OH) 2 D 3 ). Interestingly, LY294002 sensitized DU145 cells to 1,25(OH)2 D3, a cell line that is insensitive to 1,25(OH) 2 D 3 -mediated growth inhibition, leading to a strong statistically significant synergism. While neither 2.5μM LY294002 nor 10nM 1,25(OH) 2 D 3 affected the growth of DU145 cells, the combination of the two led to a 40% reduction in the number of viable cells. Rapamycin did not synergize with 1,25(OH) 2 D 3 in the growth inhibition suggesting that the mTOR pathway is not involved in the mechanism. Immunoblot analysis showed that 1,25(OH) 2 D 3 alone was able to decrease AKT phosphorylation in prostate cancer cells. In DU145 cells LY294002 and 1,25(OH) 2 D 3 cooperatively inhibited the phosphorylation of AKT. Taken together we conclude that inhibition of the PI3K/AKT pathway synergizes with the antiproliferative actions of 1,25(OH) 2 D 3 in prostate cancer cell lines possibly by additive reduction of AKT phosphorylation. The findings from the present study provide the rationale for the development of improved combinational therapeutic interventions utilizing 1,25(OH) 2 D 3 or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.

Dual Inhibition of BRD4 and PI3K by SF2523 Suppresses Human Prostate Cancer Cell Growth in Vitro and in Vivo

Dual Inhibition of BRD4 and PI3K-AKT by SF2523 Suppresses Human Renal Cell Carcinoma Cell Growth

Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Nkx3.1 and P27kip1cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen–Independent Prostate Cancer Cells

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Dual Inhibiting Oct4 and Akt Potently Suppresses the Propagation of Human Cancer Cells

Inhibition of BRD4 Suppresses Tumor Growth in Prostate Cancer Via the Enhancement of FOXO1 Expression.

Selective Targeting of the Androgen Receptor-Dna Binding Domain by the Novel Antiandrogen SBF-1 and Inhibition of the Growth of Prostate Cancer Cells

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

1,25-dihydroxyvitamin D3 inhibits phosphorylation of AKT and synergizes with pharmacological PI3K/AKT inhibitors to suppress prostate cancer cell growth

Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer

Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells

Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis

Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

BRD4 Inhibition Sensitizes Renal Cell Carcinoma Cells to the PI3K/mTOR Dual Inhibitor VS-5584.

Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer

Abstract 7270: Combination targeting of SKP2 and KDM5B induces senescence in castration-resistant prostate cancer cells via AKT signaling

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer